ALSO NOTED: GTC announces positive ATryn data; NC biotech center to expand; FDA delays Requip XL decision; and much more...

> Shares of GTC Biotherapeutics were buoyed after the company announced positive results from a late-stage study of ATryn among patients with hereditary antithrombin deficiency undergoing high-risk surgical or childbirth procedures. Release

> The North Carolina Biotechnology Center is planning to add 25,000 square feet in order to expand its conference activity and add new workers. Report

> Forest Laboratories reported positive preliminary results from a Phase III trial of its once-daily formulation of memantine HCI for Alzheimer's. Report

> The FDA is delaying a decision on Requip XL, a reformulated Parkinson's drug from Glaxo and Skyepharma. Report

> Proteome Sciences says it has no idea what's behind recent movement in its share price. Report

> Chutes & Ladders: Altus Pharmaceuticals announced today that Sheldon Berkle has resigned as president, CEO and a member of the board of directors. Release

> Some time back, Wyeth's Pearl River, NY, facility spawned seven discrimination lawsuits. Current and former employees alleged that the company discriminated against them because they're black. Now one of those cases is in court. Report

> Researchers have overcome one of the chief obstacles to developing a vaginal gel to protect poor women from HIV infection. Report

> Researchers targeting new treatments for the common cold can now look forward to getting help from a new mouse model for the ailment. Report

> A prostate cancer vaccine developed at the University of Southern California was able to prevent the disease in 90 percent of mice engineered to develop cancer. Report

> Do generics cost more in long run? Report

And Finally... Researchers have combined the DNA of three people in one embryo, pointing the way to producing children who will be free of inherited disease. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.